NCT03187262 · REGISTRY CONDITION SEARCH

A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2022-11-23

This research study is studying Daratumumab as a possible treatment for Waldenström Macroglobulinemia.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Response Rate

→

outcome · POSTED

Progression Free Survival

→

outcome · POSTED

Number of Participants With Complete Response

→

outcome · POSTED

Number of Participants With Partial Response

→

outcome · POSTED

Number of Participants With Very Good Partial Response

→

outcome · POSTED

Number of Participants With Minor Response

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Clinicopathological diagnosis of Waldenström Macroglobulinemia (Owen et al. 2003), and meeting criteria for treatment using consensus panel criteria from the Second International Workshop on Waldenström macroglobulinemia (Kyle et al. 2003) * At least one previous treatment for WM with either documented disease progression or no response (stable disease) to the most recent treatment regimen * Measurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum IgM level of \>2 times the upper limit of normal of each institution is required * Participants with symptomatic hyperviscosity or serum IgM \>5,000 mg/dL to undergo plasmapheresis prior to treatment initiation * Age ≥18 years * ECOG performance status ≤2 (see Appendix A) * Participants must have preserved organ and marrow function as defined below: * Absolute neutrophil count ≥ 1,000/mcL * Platelets ≥ 50,000/mcL * Hemoglobin ≥ 8 g/dL * Total bilirubin ≤ 1.5 mg/dL or \< 2 mg/dL if attributable to hepatic infiltration by neoplastic disease * AST/ALT ≤ 2.5 × institutional upper limit of normal * EGFR ≥ 30 ml/min * Not on any active therapy for other malignancies with the exception of topical therapies for basal cell or squamous cell cancers of the skin. * Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or have or will have complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) while participating in the study; and 2) for at least 90 days after discontinuation from the study. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. FCBP must be referred to a qualified provider of contraceptive methods if needed. FCBP must have a negative serum pregnancy test at screening. * Able to adhere to the study visit schedule and other protocol requirements. * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Any serious medical condition, laboratory abnormality, uncontrolled intercurrent illness, or psychiatric illness/social condition that would prevent study participation. * Concurrent use of any other anti-cancer agents or treatments or any other investigational agents. * Any condition, including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. * Known CNS lymphoma. * New York Heart Association classification III or IV heart failure. * Known history of Human Immunodeficiency Virus (HIV), active infection with Hepatitis B Virus (HBV), and/or Hepatitis C Virus (HCV). * Lactating or pregnant women. * Grade \>2 toxicity (other than alopecia) continuing from prior anti-cancer therapy. * History of non-compliance to medical regimens.
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
* Daratumumab will be administered in three phases: Induction, consolidation and maintenance * During induction, participants will receive daratumumab on days 1, 8, 15 and 22 of each 28-day * During consolidation, daratumumab will be administered on days 1 and 15 of each 28-day cycle * During maintenance, daratumumab will be administered on day 1 of each 28-day cycle
intervention Names
Drug: Daratumumab
label
Daratumumab
type
EXPERIMENTAL

interventions

arm Group Labels
Daratumumab
description
Daratumumab is a monoclonal human antibody. Daratumumab has shown the ability to slow or stop the growth of cells that have CD38 on the cell surface when tested in laboratories
name
Daratumumab
other Names
Darzalex
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 13
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Overall Response Rate= Minor response (\>25%-50% reduction in serum IgM from baseline) + Partial Response (\>50-90% reduction in serum IgM from baseline) + Very Good Partial Response (\>90% reduction in serum IgM from baseline) + Complete Response (resolution of all symptoms, normalization of serum IgM with disappearance of IgM paraprotein, resolution of any adenopathy or splenomegaly).
measure
Overall Response Rate
time Frame
2 years

secondary Outcomes

description
Amount of time following daratumumab administration until \>25% increase in serum IgM
measure
Progression Free Survival
time Frame
4 years
description
A complete response is defined as having resolution of WM related symptoms, normalization of serum IgM levels with complete disappearance of IgM paraprotein by immunofixation, and resolution of any adenopathy or splenomegaly.
measure
Number of Participants With Complete Response
time Frame
2 years
description
Partial response (PR) is defined as achieving a ≥50% reduction in serum IgM levels.
measure
Number of Participants With Partial Response
time Frame
2 years
description
Very Good Partial Response (VGPR): is defined as ≥90% reduction in serum IgM levels, or normalization of serum IgM levels.
measure
Number of Participants With Very Good Partial Response
time Frame
2 years
description
Minor Response (MR): A minor response (MR) is defined 25-49% reduction in serum IgM levels.
measure
Number of Participants With Minor Response
time Frame
2 years

Full study description

brief Summary: This research study is studying Daratumumab as a possible treatment for Waldenström Macroglobulinemia.
detailed Description: This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The FDA (the U.S. Food and Drug Administration) has not approved Daratumumab for this specific disease but it has been approved for other uses. Daratumumab is a monoclonal human antibody. An antibody recognizes a specific protein and binds to it. Daratumumab binds to a protein called CD38 located on the surface of B cells like WM. Daratumumab has shown the ability to slow or stop the growth of cells that have CD38 on the cell surface when tested in laboratories. In this research study, the investigators are evaluating the efficacy of Daratumumab as a single agent in participants with WM that has come back or has shown no response to previous treatment.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-8eb12afe649ea0466b69
requested nct id
NCT03187262
primary nct id
NCT03187262
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
249b5431c2e53c851c8eeb1168b794990ed94d891bb21a16b1d119a7405462ac
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-8eb12afe649ea0466b69
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT03187262
occurrences
context exact
NCT03187262
end
11
exact text
NCT03187262
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/82/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
849b1275788d57b6ea6365c8dc1c31e15cd0df41fc41389827127c64e733b47b
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice